# ClinicalTrials.gov record NCT07037459

> PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07037459-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07037459-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07037459-maridebart-cafraglutide-v1.json
- Content SHA-256: `1714624192583cd9f55cb15c53f66850d80e9c500824aaed5901fe25bb49a011`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07037459 ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

## Sources

<a id="source-ctg-observation-nct07037459-2026-07-02-199638062a19"></a>
- **ClinicalTrials.gov record NCT07037459 · retained source version 2026-07-02:199638062a19e7df645ce1f76202d15ba272ee303ca7769667116afd6858e958** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07037459) (`ctg-observation-nct07037459-2026-07-02-199638062a19`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07037459." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07037459-maridebart-cafraglutide-v1.json SHA-256: 1714624192583cd9f55cb15c53f66850d80e9c500824aaed5901fe25bb49a011.